Biodesix (NASDAQ:BDSX) CEO Scott Hutton Sells 3,559 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton sold 3,559 shares of Biodesix stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total value of $35,874.72. Following the transaction, the chief executive officer owned 45,413 shares of the company’s stock, valued at $457,763.04. This represents a 7.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Scott Hutton also recently made the following trade(s):

• On Friday, January 16th, Scott Hutton sold 970 shares of Biodesix stock. The stock was sold at an average price of $8.15, for a total transaction of $7,905.50.

Biodesix Price Performance

Biodesix stock opened at $10.35 on Thursday. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. Biodesix, Inc. has a 52 week low of $3.44 and a 52 week high of $20.40. The stock has a market capitalization of $82.34 million, a P/E ratio of -1.86 and a beta of 0.67. The stock has a fifty day moving average of $8.34 and a 200-day moving average of $7.96.

Analysts Set New Price Targets

A number of analysts recently commented on BDSX shares. Wall Street Zen upgraded Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Biodesix presently has an average rating of “Moderate Buy” and a consensus target price of $32.50.

Hedge Funds Weigh In On Biodesix

A number of large investors have recently modified their holdings of the company. XTX Topco Ltd boosted its stake in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Biodesix in the 3rd quarter worth approximately $113,000. Oracle Investment Management Inc. purchased a new stake in shares of Biodesix in the 3rd quarter valued at $113,000. Aberdeen Group plc bought a new position in shares of Biodesix during the 4th quarter valued at $1,784,000. Finally, Geode Capital Management LLC grew its holdings in shares of Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock valued at $289,000 after purchasing an additional 2,235 shares during the last quarter. 20.96% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Biodesix

Here are the key news stories impacting Biodesix this week:

• Positive Sentiment: Material reduction in short interest at month end (Jan. 30): short interest fell ~48% to 249,443 shares (about 4.5% of shares outstanding), lowering immediate short‑term selling pressure and days‑to‑cover to ~0.6 days. This reduction can be supportive for the stock if sustained.
• Neutral Sentiment: February short‑interest reports show anomalous “0 shares” figures for Feb. 10–11 (likely a reporting/data error). These entries are ambiguous and should be treated cautiously until corrected by exchanges or data providers.
• Negative Sentiment: CEO Scott Hutton sold 3,559 shares (~$35,875 at ~$10.08), reducing his stake ~7.3% — a potentially negative signal for sentiment because CEO sales often rattle investors. Read More.
• Negative Sentiment: CFO Robin Harper Cowie sold 941 shares (~$9,485 at ~$10.08), a ~5.8% reduction in her holding — another executive sale that adds to downward pressure. Read More.
• Negative Sentiment: Insider Gary Anthony Pestano sold 540 shares (~$5,443 at ~$10.08), trimming his position ~5.4%. Read More.
• Negative Sentiment: Insider Kieran O’Kane sold 584 shares (~$5,887 at ~$10.08), a ~6.2% decrease in his holding. Read More.
• Negative Sentiment: CAO Chris Vazquez sold 101 shares (~$1,018 at ~$10.08), trimming ~7.6% of his position — adds to the pattern of multiple insider sales on Feb. 10. Read More.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.